{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:55:33Z","timestamp":1790834133653,"version":"4.1.0"},"reference-count":27,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,3,30]],"date-time":"2015-03-30T00:00:00Z","timestamp":1427673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Very little is known about secondary acute lymphoblastic leukaemia (s\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>). This retrospective analysis studied a cohort of s\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> patients treated at a single centre between 1994 and 2013, while comparing therapy\u2010associated <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> (t\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>) and antecedent malignancy <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> (am\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>) patients. Thirty\u2010two patients with s\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> were identified. The overall incidence was 9\u00b74% among <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> adults while T\u2010cell s\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> was rare (12% of s\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>s). The median time interval between two malignant diagnoses was 5\u00b73\u00a0years (range: 0\u00b71\u201328). In contrast to previous reports, most of the s\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>s were <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>10\u00a0+\u00a0 and without <jats:italic><jats:styled-content style=\"fixed-case\">KMT<\/jats:styled-content>2A<\/jats:italic> (<jats:italic><jats:styled-content style=\"fixed-case\">MLL<\/jats:styled-content><\/jats:italic>) abnormalities. The overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) rates of the entire cohort at 12 and 24\u00a0months from <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> diagnosis was 49% and 25%, respectively. Most patients (<jats:italic>n<\/jats:italic>\u00a0=\u00a023, 72%) received prior chemo\u2010\/radio\u2010therapy for their first malignancy (t\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>) and only 9 (28%) did not (am\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>). No significant difference was found in the incidence of B\u2010\/T\u2010 lineage <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>, extramedullary disease, blood count, and the rate of Philadelphia\u2010positive <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>, nor in the rates of complete remission (<jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b755) and <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> (<jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b797). This similarity, together with high incidence of family malignancy in both groups, raise the possibility that s\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> patients may have an inherent predisposition to malignancies and a history of previous therapy may be of lesser importance in the pathogenesis of s\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.13386","type":"journal-article","created":{"date-parts":[[2015,3,30]],"date-time":"2015-03-30T12:22:24Z","timestamp":1427718144000},"page":"50-55","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Secondary acute lymphoblastic leukaemia is constitutional and probably not related to prior therapy"],"prefix":"10.1111","volume":"170","author":[{"given":"Chezi","family":"Ganzel","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center New York NY USA"},{"name":"Shaare Zedek Medical Centre Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Devlin","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Douer","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M.","family":"Rowe","sequence":"additional","affiliation":[{"name":"Shaare Zedek Medical Centre Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan M.","family":"Stein","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,3,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26735"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03000.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01695815"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1154"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPYWC6AQC7BAVJ"},{"key":"e_1_2_7_7_1","first-page":"180","article-title":"L\u201020 protocol for adult patients with acute lymphoblastic leukemia: a protocol utilizing prognostic factors, intensive chemotherapy and autologous \u201cpurged\u201d marrow transplantation to eradicate minimal residual disease","volume":"45","author":"Gee T.","year":"1986","journal-title":"Developments in Oncology"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.3343\/kjlm.2008.28.6.425"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402918"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1962.03050070077019b"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20668"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27901"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5411.736"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01636.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200058"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.coc.0000143845.79889.33"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.3.889.889"},{"key":"e_1_2_7_18_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Development Core Team","year":"2011"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2012.11.001"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1623"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601319"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22624"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2009"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2008.0392"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1995.tb02932.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn182"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19931115)72:10<3120::AID-CNCR2820721038>3.0.CO;2-Q"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.057752"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13386","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13386","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T10:02:45Z","timestamp":1696327365000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,30]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1111\/bjh.13386"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13386","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,30]]},"assertion":[{"value":"2014-12-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-02-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-03-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}